Relapsed or refractory B-cell malignancies remain a significant therapeutic challenge, often requiring treatments that deliver durable disease control while maintaining a manageable safety profile. Zanubrutinib, a next-generation Bruton’s tyrosine kinase (BTK) inhibitor, has emerged as an important treatment option, supported by growing clinical evidence across multiple B-cell cancers.
Targeted therapies are among the treatment approaches for B-cell malignancies, and the drugs targeting Bruton’s tyrosine kinase (BTK), a key component of the B-cell receptor (BCR) signaling pathway, have been studied in multiple B-cell malignancies. BTK is implicated in B-cell malignancies through its role in B-cell survival, proliferation, migration and interaction with the tumor environment. The three most common B-cell malignancies that have been studied in the context of BTK inhibition are chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL) and Waldenström’s macroglobulinemia (WM).
Zanubrutinib is a highly selective, covalent BTK inhibitor that targets BTK to sustainably inhibit the B-cell receptor signaling pathway. To provide optimal kinase selectivity and maintain optimal BTK target occupancy to sustainably ensure pathway inhibition, Zanubrutinib was developed as a drug. Subsequent studies have evaluated Zanubrutinib in numerous malignancies and clinical situations.
Mechanistic Basis of Zanubrutinib
BTK is a critical component downstream of the B-cell receptor (BCR), necessary for the activation of a variety of signaling pathways including those involving PLCγ2, NF-κB, and MAPK. Importantly, these pathways facilitate the survival, and proliferation of B-cancer cells and their interactions with the surrounding tumor microenvironment.
Zanubrutinib use enables sustained inhibition of Bruton’s tyrosine kinase (BTK) through the formation of a covalent bond with the Cys481 residue, resulting in irreversible enzyme inactivation. This mechanism achieves complete BTK occupancy throughout the dosing interval and maintains greater than 95% BTK occupancy through concentrations. With Zanubrutinib use, the sustained suppression of B-cell receptor (BCR) signaling provides the intended therapeutic effect of BTK inhibition and supports long-term disease control.
Importantly, Zanubrutinib exhibits high selectivity for BTK over other kinases. Its design maximizes BTK inhibition with minimal activity towards other members of the kinase family to minimize potential off-target effects to ensure a favorable tolerability profile while maintaining BTK pathway inhibition to combat cancer.
Clinical Research in Relapsed or Refractory Disease
The ALPINE Phase 3 study was a clinical trial that compared Zanubrutinib with the BTK inhibitor ibrutinib (IMBRUVICA) in patients with relapsed or refractory CLL/SLL. In the study, Zanubrutinib showed longer progression-free survival and a lower rate of atrial fibrillation compared with ibrutinib, among patients with relapsed or refractory CLL/SLL. These findings from the clinical trial contribute to the evidence comparing BTK inhibitors in CLL/SLL.
Clinical trials provide the highest level of evidence that guides patient care and compares different treatment options in patients with CLL/SLL or other hematologic malignancies who have relapsed or are refractory to prior therapy. The results can be used by clinicians to help make treatment decisions in patients who have relapsed or are refractory to prior therapy and are being considered for BTK inhibitor therapy for extended periods of time. Pharmacological mechanism of action of Zanubrutinib and clinical evidence evaluating its use in WM, in addition to CLL/SLL, as well as in MCL, in MZL and in FL (as part of combination therapy).
Zanubrutinib in Mantle Cell Lymphoma
Zanubrutinib in patients with MCL who have received at least one prior therapy is under the accelerated approval pathway. Approval was based on the overall response rate and durability of response in patients treated with Zanubrutinib.
Research Across Additional B-Cell Malignancies
There is also extensive data on the Zanubrutinib use in WM, a type of B-cell lymphoproliferative disorder affecting individuals with an excess of IgM protein produced by the malignant B cells.
Additionally, Zanubrutinib has been studied in MZL and FL. For the treatment of relapsed or refractory MZL, Zanubrutinib is approved for adult patients who have received at least one prior anti-CD20-directed therapy. For the treatment of relapsed or refractory FL, Zanubrutinib is approved for adult patients with FL who have received two or more lines of systemic therapy for previously treated FL. These indications were approved under accelerated approval based on overall response rate and duration of response.
Translating Research into Clinical Considerations
The amount of data regarding Zanubrutinib has grown significantly to allow for an assessment of the therapy’s biologic and clinical action. In developing and implementing a treatment plan that includes Zanubrutinib, a complete evaluation of the evidence for this drug must include information regarding the specific type of malignancy treated, the treatment setting, the patient’s previous therapy, the outcomes measured to assess clinical benefit, the duration of clinical benefit, and potential treatment-related toxicities.
The profile of Zanubrutinib and its clinical trials as a covalent BTK inhibitor make a good starting point for the investigation of this drug in different B-cell malignancies. Based on clinical trials, Zanubrutinib has been evaluated and approved in treatment of different diseases at different treatment settings. Moreover, currently approved Zanubrutinib indications and treatment regimens for different malignancies are differential and need to be verified with current prescribing information.
Zanubrutinib is a highly selective covalent BTK inhibitor with a substantial amount of data supporting its use in a variety of indolent B-cell malignancies. The pharmacology of the drug and the results from numerous studies, including those that have led to approval in CLL/SLL, WM, MCL, MZL, and FL, will continue to guide the use of BTK inhibitors in patients with relapsed/refractory B-cell malignancies.
Medical Disclaimer: The information provided in this article is intended for educational purposes only and should not be interpreted as medical advice, clinical guidelines, or a recommendation for any specific treatment.
